Merck (MRK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Merck reported revenue of $15.78 billion for Q1 2024, an increase of 8.9% year-over-year, with EPS at $2.07 compared to $1.40 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate by 2.95%, while EPS surpassed the consensus estimate by 6.70% [1] Financial Performance Metrics - Hospital Acute Care sales for Bridion in the U.S. reached $329 million, exceeding the average estimate of $301.76 million, marking a year-over-year increase of 19.2% [3] - International sales for Bridion were $111 million, below the average estimate of $124.70 million, reflecting a year-over-year decline of 47.1% [3] - Oncology sales for Keytruda in the U.S. were $4.12 billion, matching analyst estimates and showing an 18.2% increase year-over-year [3] - Animal health segment revenues totaled $1.51 billion, slightly below the average estimate of $1.55 billion, with a year-over-year increase of 1.3% [3] - Sales for Pneumovax vaccines were $61 million, below the average estimate of $70.63 million, representing a year-over-year decline of 36.5% [3] - Sales for RotaTeq vaccines were $216 million, below the average estimate of $260.45 million, indicating a year-over-year decrease of 27.3% [3] - Sales for ProQuar/M-M-R II/Varivax vaccines were $570 million, exceeding the average estimate of $544.16 million, with an 8% year-over-year increase [3] - Sales for Gardasil vaccines were $2.25 billion, slightly below the average estimate of $2.28 billion, reflecting a 14.1% year-over-year increase [3] - Alliance revenue for Reblozyl was $71 million, surpassing the average estimate of $68.77 million, with a significant year-over-year increase of 65.1% [3] - Alliance revenue for Lenvima was $255 million, below the average estimate of $265.43 million, showing a year-over-year increase of 9.9% [3] Stock Performance - Merck's shares have returned -3.6% over the past month, compared to a -3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]